UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________________
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
| |
|
|
| Date of Report (Date of earliest event reported) |
|
October 31, 2005 |
Targeted Genetics Corporation
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Washington |
|
0-23930 |
|
91-1549568 |
(State or other jurisdiction
of incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer
Identification No.) |
| |
|
|
| 1100 Olive Way, Suite 100, Seattle, Washington |
|
98101 |
| (Address of principal executive offices)
|
|
(Zip Code) |
| |
|
|
| Registrant’s telephone number, including area code
|
|
(206) 623-7612 |
|
|
|
|
Not Applicable
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers.
On October 31, 2005, the Board of Directors of Targeted Genetics Corporation, or the
Company, appointed a new member, Dr. Michael Perry as a Class III director, for a term that expires
on the date of the Company’s 2006 annual meeting of shareholders or when his successor is duly elected and
qualified. Dr. Perry will fill the vacancy on the Board of Directors resulting from the
retirement of Mark H. Richmond, which was previously disclosed on the Company’s current report on
Form 8-K filed September 13, 2005. At this time, the Board of Directors has not yet determined on
which of its committees, if any, Dr. Perry will serve. Dr. Perry is currently Chief Development
Officer at VIA Pharmaceuticals, Inc. Dr. Perry previously served as Chairman and CEO of Extropy
Pharmaceuticals, Inc. from June 2003 to March 2005. From February 2002 to March 2003, Dr. Perry
served as President and CEO of Pharsight Corporation. From 2000 to 2002, Dr. Perry served as
Worldwide Head of Global Research and Development for Baxter
BioScience. From 1994 to 2000, Dr. Perry was President and CEO of both SyStemix Inc. and Genetic Therapy Inc., two wholly owned
subsidiaries of Novartis Corp. Prior to 1994, Dr. Perry held various management positions with
Syntex Corporation, Schering-Plough Corporation, and BioResearch Laboratories, Inc. Dr. Perry
holds a Doctor of Veterinary Medicine, a Ph.D. in Biomedical Science-CardioPulmonary Pharmacology,
and a B.S. in Physics from the University of Guelph. A copy of the Company’s press release
announcing Dr. Perry’s appointment is attached as Exhibit 99.1 to this current report and is
incorporated herein by reference.
Item 8.01 Other Events.
On October 31, 2005, the Company announced additional data from its Phase I clinical
trial of tgAAC94 in patients with inflammatory arthritis. A copy of the Company’s press release
announcing the preliminary results of the Phase I clinical trial is attached as Exhibit 99.2 to
this current report and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
| |
99.1 Press Release Dated October 31, 2005 |
| |
99.2 Press Release Dated November 1, 2005 |
2